Table 1.
Baseline characteristics of HIV-1-infected patients.
| Parameters | ABT group (n = 83) | NRTI group (n = 92) |
| Age (years) | 40.1 ± 11.3 | 39.6 ± 11.1 |
| Men | 61 (73.5) | 67 (72.8) |
| Race | ||
| Han | 79 (95.2) | 88 (95.7) |
| Others | 4 (4.8) | 4 (4.3) |
| Plasma HIV-1 RNA (log10 copies/mL) | 3.8 ± 1.0 | 3.8 ± 1.0 |
| <100,000 | 74 (89.2) | 79 (85.9) |
| ≥100,000 | 9 (10.8) | 13 (14.1) |
| CD4 T-cell count (cells/μL) | 239.5 ± 184.6 | 233.7 ± 162.1 |
| <100 | 15 (18.1) | 14 (15.2) |
| ≥100 | 68 (81.9) | 78 (84.8) |
| Time on first-line regimen (months) | 25.9 (11.2–50.4) | 31.0 (10.7–66.1) |
| Baseline resistance mutations∗ | ||
| NRTI | 53 (66.3) | 67 (75.3) |
| NNRTI | 62 (77.5) | 73 (82) |
| Primary PI mutation | 1 (1.3) | 1 (1.1) |
| NRTIs selected for use at study entry | ||
| Tenofovir and lamivudine | – | 66 (71.7) |
| Zidovudine and lamivudine | – | 24 (26.1) |
| Abacavir and lamivudine | – | 1 (1.1) |
| Tenofovir, zidovudine and lamivudine | – | 1 (1.1) |
Data are median (Q1–Q3), n (%), and mean ± standard deviation. ∗n = 80 and 89 for ABT group and NRTI group respectively; –: No data. ABT: Albuvirtide; HIV: Human immunodeficiency virus; NNRTI: Non-nucleoside/nucleotide reverse transcriptase inhibitor; NRTI: Nucleoside or nucleotide reverse transcriptase inhibitor; PI: Protease inhibitor.